Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

TY - JOUR

T1 - Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

T2 - A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

AU - Dreyling, Martin

AU - Goy, Andre

AU - Hess, Georg

AU - Kahl, Brad S.

AU - Hernández-Rivas, José Ángel

AU - Schuier, Natasha

AU - Qi, Keqin

AU - Deshpande, Sanjay

AU - Zhu, Angeline

AU - Parisi, Lori

AU - Wang, Michael L.

N1 - Funding Information: We thank Dr Simon Rule for his significant contribution to this pooled analysis, and Dr Andrew Ip for the critical review of the article. We thank the patients who participated in the trials, their families, and the investigators and study coordinators at each of the clinical sites. Writing assistance was provided by Ewa Wandzioch of Parexel and funded by Janssen Global Services, LLC. Funding Information: This study was sponsored by Janssen Research & Development. Funding Information: MD is a HemaSphere editor, served as consultant/adviser on scientific advisory boards for AstraZeneca, Bayer, BeiGene, Celgene, Genmab, Gilead Kite, Incyte, Janssen, Novartis, Roche, and MorphoSys AG, and received honoraria from Amgen, AstraZeneca, Bayer, Celgene, Gilead Kite, Janssen, Novartis, and Roche. Received institutional research funding from AbbVie, Bayer, Celgene, Gilead Kite, Janssen, and Roche. AG served as consultant for Acerta, Janssen, Novartis, Kite Pharma, Medscape, MJH Associates, Physician Education Resources, Xcenda, OncLive Peer Exchange, Pharmacyclics/AbbVie, and Intellisphere, LLC (Targeted Oncology), and participated in advisory boards for AbbVie/Pharmacyclics, AstraZeneca, BMS, Elsevier’s Practice Update Oncology, Kite Pharma, Vincerx Pharma. Received honoraria from Acerta, Janssen, Novartis, Kite Pharma, Medscape, MJH Associates, Physician Education Resources, Xcenda, OncLive Peer Exchange, Intellisphere, LLC (Targeted Oncology), AbbVie/Pharmacyclics, AstraZeneca, BMS, COTA, Elsevier’s Practice Update Oncology, Resilience, Vincerx Pharma, and Roswell Park, and institutional research funding from Acerta, AstraZeneca, Celgene, Constellation, Genentech-Hoffman La Roche, Infinity, Infinity Verastem, Janssen, Karyopharm, Kite Pharma, and Pharmacyclics. Owns stock in COTA, Resilience, and Genomics Cooperative LCA and is a member of steering committees for MorphoSys, Incyte, AstraZeneca, Physicians Education Resource, LLC-Faculty CME, and Roswell Park. GH served as an advisor for and received honoraria from Janssen, Celgene, Roche, Takeda, Amgen, AbbVie, AstraZeneca, and Gilead/Kite and received institutional research support by Roche, Janssen, AbbVie, and Morphosys/Incyte. BSK served as consultant for AbbVie, AstraZeneca, Janssen, Pharmacyclics, BeiGene, MEI, TG Therapeutics, Genentech, and Celgene. Received research funding from AstraZeneca and BeiGene. J-AH-R served as consultant on scientific advisory boards for Janssen, Roche, AbbVie, AstraZeneca, Beigene, Lilly, Gilead, BMS-Celgene, Amgen, Takeda, Jazz Pharmaceuticals, and Rovi. Received honoraria from Janssen, Roche, AbbVie, AstraZeneca, Lilly, Gilead, BMS-Celgene, Amgen, Takeda, and Astra Zeneca. Received research funding from BMS-Celgene and Sanofi. MLW served as a consultant for AstraZeneca, Bayer Healthcare, BeiGene, CSTone, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno, Kite Pharma, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pharmacyclics, and VelosBio. Received honoraria from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Epizyme, Hebei Cancer Prevention Federation, Imbruvica, Imedex, Janssen, Kite Pharma, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals, OMI, Physicians Education Resources (PER), Scripps, The First Afflicted Hospital of Zhejiang University, BGICS. Received research funding from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Innocare, Janssen, Juno, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, and VelosBio. KQ, SD, LP, NS, and AZ are employees of Janssen.

PY - 2022/5/13

Y1 - 2022/5/13

UR - http://www.scopus.com/inward/record.url?scp=85129575321&partnerID=8YFLogxK

U2 - 10.1097/HS9.0000000000000712

DO - 10.1097/HS9.0000000000000712

M3 - Letter

C2 - 35441128

AN - SCOPUS:85129575321

SN - 2572-9241

VL - 6

SP - E712

JO - HemaSphere

JF - HemaSphere

IS - 5

ER -